Selective Targeting of the JAK2V617F Mutation in Polycythemia Vera and Essential Thrombocythemia by ITF2357, a Novel Histone Deacetylase Inhibitor.
Vittoria Guerini(Azienda Ospedaliero-Universitaria delle Marche), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Martino Introna(Mario Negri Institute for Pharmacological Research), Tiziano Barbui(University of Bergamo), Chiara Maria Dellacasa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Anna Salvi(Azienda Ospedaliero-Universitaria delle Marche), Orietta Spinelli(Ospedale Papa Giovanni XXIII), Valentina Barbui(Azienda Ospedaliero-Universitaria delle Marche), Josée Golay(Azienda Ospedaliero Universitaria Ospedali Riuniti)
Cited by 5
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k